In vitro permeation characteristics of moxifloxacin from oil drops through excised goat, sheep, buffalo and rabbit corneas

Pharmazie

Volumn 62, Issue 11, 2007, Pages 853-857

  Pawar, P K ^a   Majumdar, Dipak K ^a  

^a UNIVERSITY OF DELHI   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIS OIL; BENZYL ALCOHOL; CASTOR OIL; COTTON SEED OIL; MOXIFLOXACIN; SESAME SEED OIL; SOYBEAN OIL; SUNFLOWER OIL;

ANIMAL TISSUE; ARTICLE; BUFFALO; CONTROLLED STUDY; CORNEA; DRUG FORMULATION; DRUG SOLUBILITY; GOAT; IN VITRO STUDY; NONHUMAN; RABBIT; SHEEP; SPECTROPHOTOMETRY;

ANIMALS; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; BENZYL ALCOHOLS; BUFFALOES; CHEMISTRY, PHYSICAL; CORNEA; GOATS; OILS; PERMEABILITY; QUINOLINES; RABBITS; SHEEP; SOLUTIONS;

EID: 36348999149     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2007.11.7055     Document Type: Article

References (16)

1. Biedenbach DJ, Jones RN (1996) The comparative antimicrobial activity of levofloxacin tested against 350 clinical isolates of Streptococci. Diagn Microbiol Infect Dis 25: 47-51.
2. Dajcs JJ, Thibodeaux BA, Marquait ME, Girgis DO, Traiedj M, O'Callaghan RJ (2004) Effectiveness of ciprofloxacin, levofloxacin or moxifloxacin for treatment of experimental Staphylococcus aureus keratitis. Antimicrob Agents Chemother 48: 1948-1952.
3. Dalhoff A, Petersen U, Endermann R (1996) In vitro activity of Bay 12-8039, a new 8-methoxyquinolone. Chemotherapy 42: 410-425.
4. Davis R, Bryson HM (1994) Levofloxacin: a review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 47: 677-700.
5. Hardman JG, Limbird LE (2001) Goodman & Gillman's, The Pharmacological Basis of Therapeutics. McGraw-Hill, New York.
6. nded., Marcel Dekker, New York, pp. 539-603.
7. Kowalski RP, Dhaliwal DK, Karenchak LM, Romanowski EG, Mah FS, Ritterband DC, Gordon YJ (2003) Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol 136: 500-505.
8. Kowalski RP, Romanowski EG, Mah FS, Yates KA, Gordon YJ (2004) Topical prophylaxis with moxifloxacin prevents endophthalmitis in a rabbit model. Am J Ophthalmol 138: 33-37.
9. th ed., Mack Publishing company, Easton, Pennsylvania, p. 1687.
10. Mather R, Stewart JM, Tisha P, Wong J, Stephen DM (2004) The effect of cataract surgery on ocular levels of topical moxifloxacin. Am J Ophthalmol 138: 554-559.
11. Malhotra M, Majumdar DK (1997) In vitro transcorneal permeation of ketorolac tromethamine from buffered and unbuffered aqueous ocular drops. Indian J Exp Biol 35: 941-947.
12. Maurice DM, Riley MV (1970) Ocular Pharmacokinetics. In: Graymore CN (ed.) Biochemistry of the Eye. Academic Press, London, UK, pp. 6-16.
13. McCulley JP, Caudle D, Aronowicz JD, Shine WE (2006) Fourth generation fluroroquinolone penetration into the aqueous humor in humans. Ophthalmology 113: 955-959.
14. Pawar PK, Majumdar DK (2006) Effect of formulation factors on in vitro permeation of moxifloxacin from aqueous drops through excised goat, sheep, and buffalo corneas. AAPS Pharm Sci Tech. 7: E13.
15. Smith SA, Smith SE, Lazare R (1978) An increased effect of pilocarpine on the pupil by application of the drug in oil. Br J Ophthalmol 62: 314-317.
16. Yagci R, Oflu Y, Dincel A, Kaya E, Yagci S, Bayer B, Duman S, Bozkurt A (2006) Penetration of second-third and fourth generation topical fluroroquinolone into aqueous and vitrous humor in rabbit endophtalmitis model. Eye. May 26. (Epub ahead of print) doi: 10.1038/sj.eye.6702414.